

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:

BRISTOL-MYERS SQUIBB COMPANY
Attn. D'Amico, Stephen
P.O. Box 4000
RT. 206 And Provinceline Road
Princeton, NJ 08543-4000
UNITED STATES OF AMERICA

RECEIVED BMIS PATENT LAW

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

2127 FEB 25 2003

Docketed Item

Due Date

Attorney

(PCT Rule 44.1)
US-105-(NP) 5/26/03
105-DOUGLAS (CIP) 5/20/03

Date of mailing
(day/month/year)

20/02/2003

Applicant's or agent's file reference

D0067

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/US 01/49740

International filing date

(day/month/year)

20/12/2001

Applicant

BRISTOL-MYERS SQUIBB COMPANY

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase, before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 po nl,
Fax: (+31-70) 340-3016

Authorized officer

Wolfgang Hingel

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference D0067	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 01/ 49740	International filing date (day/month/year) 20/12/2001	(Earliest) Priority Date (day/month/year) 22/12/2000
Applicant BRISTOL-MYERS SQUIBB COMPANY		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IS 01/49740

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C12N15/63 C07K16/18 G01N33/50
A61K38/17 C12N15/11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

SEQUENCE SEARCH, EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	INOHARA ET AL: "Nod 1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 21, 21 May 1999 (1999-05-21), pages 14560-14567, XP002156656 ISSN: 0021-9258 the whole document -----	1-14, 16-23

☐ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

14 February 2003

Date of mailing of the international search report

20/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sprinks, M

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 12 and 13 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 11 and 21-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 15

Present claim 15 relates to polynucleotides defined solely by reference to a desirable characteristic or property, namely the ability to encode proteins with "altered" caspase binding activity i.e. covering proteins with completely undefined structures and anything from improved activity to no activity at all.

Said claim covers all polynucleotides having this characteristic or property, whereas the application provides no support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for them. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the polynucleotides by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/49740

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 15
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/08631

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12N 15/00, 15/12 US CL : 536/23.1, 23.5; 435/6, 320.1, 325 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.1, 23.5; 435/6, 320.1, 325 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) NONE																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X, P --- A	Database Genbank, Accession No. AL135937, 15 March 2001 (15.03.2001), particularly nucleotides 29925 through 30325.	1-8 ----- 9, 19																		
X --- A	Database Genbank, Accession No. AA004350, HILLIER et al., Generation and analysis of 280,000 Human Expressed Sequence Tags. Genome Res. 07 May 1997 (07.05.1997), Vol. 6, No. 9, pages 807-828.	1-8 ----- 9, 19																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"><tr><td>* Special categories of cited documents:</td><td>-T-</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>-A- document defining the general state of the art which is not considered to be of particular relevance</td><td>-X-</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>-E- earlier application or patent published on or after the international filing date</td><td>-Y-</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>-L- document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>-&-</td><td>document member of the same patent family</td></tr><tr><td>-O- document referring to an oral disclosure, use, exhibition or other means</td><td></td><td></td></tr><tr><td>-P- document published prior to the international filing date but later than the priority date claimed</td><td></td><td></td></tr></table>			* Special categories of cited documents:	-T-	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	-A- document defining the general state of the art which is not considered to be of particular relevance	-X-	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	-E- earlier application or patent published on or after the international filing date	-Y-	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	-L- document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	-&-	document member of the same patent family	-O- document referring to an oral disclosure, use, exhibition or other means			-P- document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	-T-	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
-A- document defining the general state of the art which is not considered to be of particular relevance	-X-	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
-E- earlier application or patent published on or after the international filing date	-Y-	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
-L- document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	-&-	document member of the same patent family																		
-O- document referring to an oral disclosure, use, exhibition or other means																				
-P- document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 23 October 2001 (23.10.2001)		Date of mailing of the international search report 02 JAN 2002																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer <i>Marianne P. Allen</i> Telephone No. 703-308-0196																		

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/08631

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-9 and 19 with respect to SEQ ID NO: 1

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/08631

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-9 and 19, drawn to polynucleotides.

Group II, claim(s) 10-11, drawn to polypeptides.

Group III, claim(s) 12, drawn to antibodies.

Group IV, claim(s) 13-15, drawn to methods of detecting polynucleotides.

Group V, claim(s) 16, drawn to methods of detecting polypeptides.

Group VI, claim(s) 17, drawn to a first method of identifying compounds that bind.

Group VII, claim(s) 18, drawn to a second method of identifying compounds that bind.

Group VIII, claim(s) 20-21, drawn to polypeptide arrays.

Group IX, claim(s) 22-26, drawn to polynucleotide arrays.

Group X, claim(s) 27, drawn to a method of treatment using a polypeptide.

Group XI, claim(s) 28, drawn to a method of treatment using an antibody.

In addition, each of the SEQ ID NOS. named in the groups is considered to be a separate invention and applicant must elect a single SEQ ID NO. or for Groups VIII and IX a specific combination of SEQ ID NOS. for searching. Due to the burden of search for sequences, only a single SEQ ID NO. or specific combination of SEQ ID NOS. for Groups VIII and IX is considered to meet unity of invention.

The inventions listed as Groups I-XI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Each of the products of Groups I-III, VIII, and IX differ structurally and functionally and thus lack the same or corresponding special technical feature. Each of the methods of Groups IV-VII, X and XI have different starting materials, method steps, and goals and thus lack the same or corresponding special technical feature.

As each SEQ ID NO. does not appear to share a common core structure, they are considered to be structurally and functionally distinct invention.

The number of inventions has been determined as follows: Each of groups I-XI is directed to 30368 SEQ ID NOS. As such, 30368 SEQ ID NOS. X 11 groups results in 334048 inventions.

If no additional fees are paid, Group I, claims 1-9 and 19, will be searched with respect to SEQ ID NO: 1. If Group VIII is elected, the default polypeptide array is considered to be an array comprising all of SEQ ID NOS: 30369-60736. If Group IX is elected, the default polynucleotide array is considered to be an array comprising all of SEQ ID NOS: 1-30368. Applicant is advised that they should specifically identify each additional group and each additional SEQ ID NO. being paid for. With respect to Groups VIII and IX, applicant should specifically identify each subset of SEQ ID NOS. present on the arrays if additional combinations are to be searched.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/12545

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C07K14/47 C07K16/18 A61K48/00 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

X	MASUMOTO J ET AL: "ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 48, 26 November 1999 (1999-11-26), pages 33835-33838, XP002191744 ISSN: 0021-9258 the whole document	1-19
Y	& DATABASE EMBL [Online] 1 December 1999 (1999-12-01) retrieved from EBI Database accession no. AB023416 abstract	1-19

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 September 2002

Date of mailing of the international search report

16. 01. 03

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rutz, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/12545

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DATABASE EMBL [Online] 3 September 1998 (1998-09-03) retrieved from EBI Database accession no. AF086332 XP002213126 abstract	1-19
A	--- INOHARA N ET AL: "Genes with homology to mammalian apoptosis regulators identified in zebrafish." CELL DEATH AND DIFFERENTIATION. ENGLAND MAY 2000, vol. 7, no. 5, May 2000 (2000-05), pages 509-510, XP002213121 ISSN: 1350-9047 the whole document	1-19
A	--- DATABASE EPOP [Online] 5 September 2000 (2000-09-05) retrieved from EBI Database accession no. AX017324 XP002213127 abstract & WO 99 47669 A (SCHMITT ARMIN ET AL.) 23 September 1999 (1999-09-23)	1-19
A	--- HOFMANN K: "The modular nature of apoptotic signaling proteins" CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, BASEL, CH, vol. 55, July 1999 (1999-07), pages 1113-1128, XP002171651 ISSN: 1420-682X the whole document	1-19
P,X	--- DATABASE GSP [Online] 9 March 2001 (2001-03-09) retrieved from EBI Database accession no. AAB36608 XP002213128 abstract	1-19
E	& WO 00 70047 A (INCYTE GENOMICS INC.) 23 November 2000 (2000-11-23)	1-19
P,X	--- PAWLOWSKI K ET AL: "PAAD - a new protein domain associated with apoptosis, cancer and autoimmune diseases." TRENDS IN BIOCHEMICAL SCIENCES. ENGLAND FEB 2001, vol. 26, no. 2, February 2001 (2001-02), pages 85-87, XP002213122 ISSN: 0968-0004 the whole document figure 1	1-19

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/12545

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	MASUMOTO J ET AL: "Pyrin N-terminal homology domain- and caspase recruitment domain-dependent oligomerization of ASC." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 26 JAN 2001, vol. 280, no. 3, 26 January 2001 (2001-01-26), pages 652-655, XP002213123 ISSN: 0006-291X the whole document ---	1-19
P,A	BERTIN J ET AL: "THE PYRIN DOMAIN: A NOVEL MOTIF FOUND IN APOPTOSIS AND INFLAMMATION PROTEINS" CELL DEATH AND DIFFERENTIATION, EDWARD ARNOLD, OXFORD, GB, vol. 12, no. 7, December 2000 (2000-12), pages 1273-1274, XP008006072 ISSN: 1350-9047 the whole document ---	1-19
P,A	FAIRBROTHER W J ET AL: "THE PYRIN DOMAIN: A MEMBER OF THE DEATH DOMAIN-FOLD SUPERFAMILY" PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 9, no. 10, September 2001 (2001-09), pages 1911-1918, XP008006069 ISSN: 0961-8368 the whole document ---	1-19
P,A	STAUB E ET AL: "The DAPIN family: a novel domain links apoptotic and interferon response proteins." TRENDS IN BIOCHEMICAL SCIENCES. ENGLAND FEB 2001, vol. 26, no. 2, February 2001 (2001-02), pages 83-85, XP002213124 ISSN: 0968-0004 the whole document ---	1-19
P,A	MARTINON F ET AL: "The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation." CURRENT BIOLOGY: CB. ENGLAND 20 FEB 2001, vol. 11, no. 4, 20 February 2001 (2001-02-20), pages R118-R120, XP002213125 ISSN: 0960-9822 the whole document -----	1-19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 01/12545

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although Claims 17-19 relate to a method for treatment of the human or animal body, the search was carried out on the basis of the alleged effects of the compound or composition.
2. ☒ Claims Nos.: 20-23
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

See additional sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

X

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims 1-19 (partly)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 01/12545

Continuation of I.2

Claims: 20-23

Claims 20-23 are directed to compounds that block the specific interaction of PYD domains for intracellular signal transduction, and to medical use thereof. A search appears possible for want of any indication of sufficient structural features of such a compound.

The applicant is advised that claims or parts of claims relating to inventions in respect of which no international search report has been established normally cannot be the subject of an international preliminary examination (PCT Rule 66.1(e)). In its capacity as International Preliminary Examining Authority the EPO generally will not carry out a preliminary examination for subjects that have not been searched. This also applies to cases where the claims were amended after receipt of the international search report (PCT Article 19) or where the applicant submits new claims in the course of the procedure under PCT Chapter II.

1. Claims: Invention 1: Claims 1-19 (in part)

DNA sequence coding for human PYC protein (SEQ ID NO: 2), expression vectors, host cells, gene product (SEQ ID NO: 1), antibodies, method of isolating the gene product, method of expressing the gene product, medical use of the DNA sequence or of the gene product.

2. Claims: Invention 2: Claims 1-19 (in part)

DNA sequence coding for human pyrin protein (SEQ ID NO: 4), expression vectors, host cells, gene product (SEQ ID NO: 3), antibodies, method of isolating the gene product, method of expressing the gene product, medical use of the DNA sequence or of the gene product.

3. Claims: Invention 3: Claims 1-19 (in part)

DNA sequence coding for human PYCARD protein (SEQ ID NO: 6), expression vectors, host cells, gene product (SEQ ID NO: 5), antibodies, method of isolating the gene product, method of expressing the gene product, medical use of the DNA sequence or of the gene product.

4. Claims: Inventions 4-20: Claims 1-19 (in part)

analogously for DNA sequences with SEQ ID NO: 8, 10, 12, ..., 38, 40.

5. Claims: Invention 21: Claims 11-14 and 17-19 (in part)

gene product containing an amino acid sequence for a PYD domain from the mouse pyrin protein (SEQ ID NO: 60, pycard.mm), antibodies, medical use of the gene product.

6. Claims: Invention 21: Claims 11-14 and 17-19 (in part)

gene product containing an amino acid sequence for a PYD domain from the mouse pyrin protein (SEQ ID NO: 60, pycard.mm), antibodies, medical use of the gene product.

7. Claims: Inventions 23-26: Claims 11-14 and 17-19 (in part)

analogously for gene products with SEQ ID NO: 63, 82, 83, 84.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/12545

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9947669 A	23-09-1999	DE 19813839 A	23-09-1999
		EP 1236799 A	04-09-2002
		EP 1064379 A	03-01-2001
		JP 2002506643 T	05-03-2002

WO 0070047 A	23-11-2000	AU 5134600 A	05-12-2000
		EP 1179065 A	13-02-2002
		US 2002076762 A	20-06-2002

INTERNATIONALER RECHERCHENBERICHT

Internationales Aktenzeichen
PCT/EP 01/12545

A. KLASSIFIZIERUNG DES ANMELDUNGSGEGENSTANDES
IPK 7 C12N15/12 C07K14/47 C07K16/18 A61K48/00 A61K38/17

Nach der Internationalen Patentklassifikation (IPK) oder nach der nationalen Klassifikation und der IPK

B. RECHERCHIERTE GEBIETE

Recherchierter Mindestprüfstoff (Klassifikationssystem und Klassifikationssymbole)
IPK 7 C12N C07K A61K

Recherchierte aber nicht zum Mindestprüfstoff gehörende Veröffentlichungen, soweit diese unter die recherchierten Gebiete fallen

Während der internationalen Recherche konsultierte elektronische Datenbank (Name der Datenbank und evtl. verwendete Suchbegriffe)

C. ALS WESENTLICH ANGESEHENE UNTERLAGEN

Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
X	MASUMOTO J ET AL: "ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, Bd. 274, Nr. 48, 26. November 1999 (1999-11-26), Seiten 33835-33838, XP002191744 ISSN: 0021-9258 das ganze Dokument	1-19
Y	& DATABASE EMBL 'Online! 1. Dezember 1999 (1999-12-01) retrieved from EBI Database accession no. AB023416 Zusammenfassung ---	1-19

☒ Weitere Veröffentlichungen sind der Fortsetzung von Feld C zu entnehmen

☐ Siehe Anhang Patentfamilie

- * Besondere Kategorien von angegebenen Veröffentlichungen :
 - *A* Veröffentlichung, die den allgemeinen Stand der Technik definiert, aber nicht als besonders bedeutsam anzusehen ist
 - *E* älteres Dokument, das jedoch erst am oder nach dem internationalen Anmeldedatum veröffentlicht worden ist
 - *L* Veröffentlichung, die geeignet ist, einen Prioritätsanspruch zweifelhaft erscheinen zu lassen, oder durch die das Veröffentlichungsdatum einer anderen im Recherchenbericht genannten Veröffentlichung belegt werden soll oder die aus einem anderen besonderen Grund angegeben ist (wie ausgeführt)
 - *O* Veröffentlichung, die sich auf eine mündliche Offenbarung, eine Benutzung, eine Ausstellung oder andere Maßnahmen bezieht
 - *P* Veröffentlichung, die vor dem internationalen Anmeldedatum, aber nach dem beanspruchten Prioritätsdatum veröffentlicht worden ist

- *T* Spätere Veröffentlichung, die nach dem internationalen Anmeldedatum oder dem Prioritätsdatum veröffentlicht worden ist und mit der Anmeldung nicht kollidiert, sondern nur zum Verständnis des der Erfindung zugrundeliegenden Prinzips oder der ihr zugrundeliegenden Theorie angegeben ist
- *X* Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann allein aufgrund dieser Veröffentlichung nicht als neu oder auf erfinderscher Tätigkeit beruhend betrachtet werden
- *Y* Veröffentlichung von besonderer Bedeutung; die beanspruchte Erfindung kann nicht als auf erfinderscher Tätigkeit beruhend betrachtet werden, wenn die Veröffentlichung mit einer oder mehreren anderen Veröffentlichungen dieser Kategorie in Verbindung gebracht wird und diese Verbindung für einen Fachmann naheliegend ist
- *G* Veröffentlichung, die Mitglied derselben Patentfamilie ist

Datum des Abschlusses der internationalen Recherche

11. September 2002

Absendedatum des internationalen Recherchenberichts

16. 01. 03

Name und Postanschrift der Internationalen Recherchenbehörde
Europäisches Patentamt, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Bevollmächtigter Beauftragter

Rutz, B

INTERNATIONALER RECHERCHENBERICHT

Internationales Aktenzeichen

PCT/EP 01/12545

C.(Fortsetzung) ALS WESENTLICH ANGESEHENE UNTERLAGEN		
Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
Y	<p>DATABASE EMBL 'Online! 3. September 1998 (1998-09-03) retrieved from EBI Database accession no. AF086332 XP002213126 Zusammenfassung</p>	1-19
A	<p>INOHARA N ET AL: "Genes with homology to mammalian apoptosis regulators identified in zebrafish." CELL DEATH AND DIFFERENTIATION. ENGLAND MAY 2000, Bd. 7, Nr. 5, Mai 2000 (2000-05), Seiten 509-510, XP002213121 ISSN: 1350-9047 das ganze Dokument</p>	1-19
A	<p>DATABASE EPOP 'Online! 5. September 2000 (2000-09-05) retrieved from EBI Database accession no. AX017324 XP002213127 Zusammenfassung & WO 99 47669 A (SCHMITT ARMIN ET AL.) 23. September 1999 (1999-09-23)</p>	1-19
A	<p>HOFMANN K: "The modular nature of apoptotic signaling proteins" CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, BASEL, CH, Bd. 55, Juli 1999 (1999-07), Seiten 1113-1128, XP002171651 ISSN: 1420-682X das ganze Dokument</p>	1-19
P,X	<p>DATABASE GSP 'Online! 9. März 2001 (2001-03-09) retrieved from EBI Database accession no. AAB36608 XP002213128 Zusammenfassung</p>	1-19
E	<p>& WO 00 70047 A (INCYTE GENOMICS INC.) 23. November 2000 (2000-11-23)</p>	1-19
P,X	<p>PAWLOWSKI K ET AL: "PAAD - a new protein domain associated with apoptosis, cancer and autoimmune diseases." TRENDS IN BIOCHEMICAL SCIENCES. ENGLAND FEB 2001, Bd. 26, Nr. 2, Februar 2001 (2001-02), Seiten 85-87, XP002213122 ISSN: 0968-0004 das ganze Dokument Abbildung 1</p>	1-19

INTERNATIONALER RECHERCHENBERICHT

Internationales Aktenzeichen

PCT/EP 01/12545

C.(Fortsetzung) ALS WESENTLICH ANGESEHENE UNTERLAGEN

Kategorie*	Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	Betr. Anspruch Nr.
P,A	MASUMOTO J ET AL: "Pyrin N-terminal homology domain- and caspase recruitment domain-dependent oligomerization of ASC." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 26 JAN 2001, Bd. 280, Nr. 3, 26. Januar 2001 (2001-01-26), Seiten 652-655, XP002213123 ISSN: 0006-291X das ganze Dokument	1-19
P,A	BERTIN J ET AL: "THE PYRIN DOMAIN: A NOVEL MOTIF FOUND IN APOPTOSIS AND INFLAMMATION PROTEINS" CELL DEATH AND DIFFERENTIATION, EDWARD ARNOLD, OXFORD, GB, Bd. 12, Nr. 7, Dezember 2000 (2000-12), Seiten 1273-1274, XP008006072 ISSN: 1350-9047 das ganze Dokument	1-19
P,A	FAIRBROTHER W J ET AL: "THE PYRIN DOMAIN: A MEMBER OF THE DEATH DOMAIN-FOLD SUPERFAMILY" PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, Bd. 9, Nr. 10, September 2001 (2001-09), Seiten 1911-1918, XP008006069 ISSN: 0961-8368 das ganze Dokument	1-19
P,A	STAUB E ET AL: "The DAPIN family: a novel domain links apoptotic and interferon response proteins." TRENDS IN BIOCHEMICAL SCIENCES. ENGLAND FEB 2001, Bd. 26, Nr. 2, Februar 2001 (2001-02), Seiten 83-85, XP002213124 ISSN: 0968-0004 das ganze Dokument	1-19
P,A	MARTINON F ET AL: "The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation." CURRENT BIOLOGY: CB. ENGLAND 20 FEB 2001, Bd. 11, Nr. 4, 20. Februar 2001 (2001-02-20), Seiten R118-R120, XP002213125 ISSN: 0960-9822 das ganze Dokument	1-19

INTERNATIONALER RECHERCHENBERICHT

Internationales Aktenz. 1979
PCT/EP 01/12545

Feld I Bemerkungen zu den Ansprüchen, die sich als nicht recherchierbar erwiesen haben (Fortsetzung von Punkt 2 auf Blatt 1)

Gemäß Artikel 17(2)a) wurde aus folgenden Gründen für bestimmte Ansprüche kein Recherchenbericht erstellt:

1. ☒ Ansprüche Nr.
 weil sie sich auf Gegenstände beziehen, zu deren Recherche die Behörde nicht verpflichtet ist, nämlich

 Obwohl die Ansprüche 17-19 sich auf ein Verfahren zur Behandlung des menschlichen/tierischen Körpers beziehen, wurde die Recherche durchgeführt und gründete sich auf die angeführten Wirkungen der Verbindung/Zusammensetzung.
2. ☒ Ansprüche Nr. 20-23
 weil sie sich auf Teile der internationalen Anmeldung beziehen, die den vorgeschriebenen Anforderungen so wenig entsprechen, daß eine sinnvolle internationale Recherche nicht durchgeführt werden kann, nämlich

 siehe Zusatzblatt WEITERE ANGABEN PCT/ISA/210
3. ☐ Ansprüche Nr.
 weil es sich dabei um abhängige Ansprüche handelt, die nicht entsprechend Satz 2 und 3 der Regel 6.4 a) abgefaßt sind.

Feld II Bemerkungen bei mangelnder Einheitlichkeit der Erfindung (Fortsetzung von Punkt 3 auf Blatt 1)

Die internationale Recherchenbehörde hat festgestellt, daß diese internationale Anmeldung mehrere Erfindungen enthält:

1. ☐ Da der Anmelder alle erforderlichen zusätzlichen Recherchegebühren rechtzeitig entrichtet hat, erstreckt sich dieser internationale Recherchenbericht auf alle recherchierbaren Ansprüche.
2. ☐ Da für alle recherchierbaren Ansprüche die Recherche ohne einen Arbeitsaufwand durchgeführt werden konnte, der eine zusätzliche Recherchegebühr gerechtfertigt hätte, hat die Behörde nicht zur Zahlung einer solchen Gebühr aufgefordert.
3. ☐ Da der Anmelder nur einige der erforderlichen zusätzlichen Recherchegebühren rechtzeitig entrichtet hat, erstreckt sich dieser internationale Recherchenbericht nur auf die Ansprüche, für die Gebühren entrichtet worden sind, nämlich auf die Ansprüche Nr.
4. ☒ Der Anmelder hat die erforderlichen zusätzlichen Recherchegebühren nicht rechtzeitig entrichtet. Der internationale Recherchenbericht beschränkt sich daher auf die in den Ansprüchen zuerst erwähnte Erfindung; diese ist in folgenden Ansprüchen erfaßt:

 Ansprüche 1-19 (teilweise)

Bemerkungen hinsichtlich eines Widerspruchs

- ☐ Die zusätzlichen Gebühren wurden vom Anmelder unter Widerspruch gezahlt.
- ☐ Die Zahlung zusätzlicher Recherchegebühren erfolgte ohne Widerspruch.

WEITERE ANGABEN

PCT/ISA/ 210

Fortsetzung von Feld I.2

Ansprüche Nr.: 20-23

Ansprüche 20-23 sind auf Verbindungen gerichtet, die die spezifische Interaktion von PYD-Domänen zur intrazellulären Signalweiterleitung blockieren bzw. auf deren medizinische Verwendung. Da keine ausreichenden strukturellen Merkmale solcher Verbindung angegeben wurden, erscheint eine Recherche nicht möglich.

Der Anmelder wird darauf hingewiesen, daß Patentansprüche, oder Teile von Patentansprüchen, auf Erfindungen, für die kein internationaler Recherchenbericht erstellt wurde, normalerweise nicht Gegenstand einer internationalen vorläufigen Prüfung sein können (Regel 66.1(e) PCT). In seiner Eigenschaft als mit der internationalen vorläufigen Prüfung beauftragte Behörde wird das EPA also in der Regel keine vorläufige Prüfung für Gegenstände durchführen, zu denen keine Recherche vorliegt. Dies gilt auch für den Fall, daß die Patentansprüche nach Erhalt des internationalen Recherchenberichtes geändert wurden (Art. 19 PCT), oder für den Fall, daß der Anmelder im Zuge des Verfahrens gemäß Kapitel II PCT neue Patentanprüche vorlegt.

WEITERE ANGABEN

PCT/ISA/ 210

1. Ansprüche: Erfindung 1: Ansprüche 1-19 (teilweise)

DNA-Sequenz kodierend für menschliches Pyc Protein (SEQ ID NO: 2), Expressionsvektoren, Wirtszellen, Genprodukt (SEQ ID NO: 1), Antikörper, Verfahren zur Isolierung des Genprodukts, Verfahren zur Expression des Genprodukts, medizinische Verwendung der DNA-Sequenz oder des Genprodukts

2. Ansprüche: Erfindung 2: Ansprüche 1-19 (teilweise)

DNA-Sequenz kodierend für menschliches Pyrin Protein (SEQ ID NO: 4), Expressionsvektoren, Wirtszellen, Genprodukt (SEQ ID NO: 3), Antikörper, Verfahren zur Isolierung des Genprodukts, Verfahren zur Expression des Genprodukts, medizinische Verwendung der DNA-Sequenz oder des Genprodukts

3. Ansprüche: Erfindung 3: Ansprüche 1-19 (teilweise)

DNA-Sequenz kodierend für menschliches Pycard Protein (SEQ ID NO: 6), Expressionsvektoren, Wirtszellen, Genprodukt (SEQ ID NO: 5), Antikörper, Verfahren zur Isolierung des Genprodukts, Verfahren zur Expression des Genprodukts, medizinische Verwendung der DNA-Sequenz oder des Genprodukts

4. Ansprüche: Erfindungen 4-20: Ansprüche 1-19 (teilweise)

analog für DNA-Sequenzen mit SEQ ID NO: 8, 10, 12, ... , 38, 40

5. Ansprüche: Erfindung 21: Ansprüche 11-14, 17-19 (teilweise)

Genprodukt enthaltend eine Aminosäuresequenz für eine PYD-Domäne aus dem Pyrin-Protein der Maus (SEQ ID NO: 60, Pycard.mm), Antikörper, medizinische Verwendung des Genprodukts

6. Ansprüche: Erfindung 22: Ansprüche 11-14, 17-19 (teilweise)

Genprodukt enthaltend eine Aminosäuresequenz für eine PYD-Domäne aus dem Pyrin-Protein der Ratte (SEQ ID NO: 61, Pycard.mm), Antikörper, medizinische Verwendung des Genprodukts

7. Ansprüche: Erfindungen 23-26: Ansprüche 11-14, 17-19 (teilweise)

analog für Genprodukte mit SEQ ID NO: 63, 82, 83, 84

INTERNATIONALER RECHERCHENBERICHT

Angaben zu Veröffentlichungen, die zur selben Patentfamilie gehören

Internationales Aktenzeichen

PCT/EP 01/12545

Im Recherch nbericht angeführt s Pat ntdokument	Datum der Veröffentlichung	Mitglied(er) der Patentfamilie	Datum der Veröffentlichung
WO 9947669 A	23-09-1999	DE 19813839 A	23-09-1999
		EP 1236799 A	04-09-2002
		EP 1064379 A	03-01-2001
		JP 2002506643 T	05-03-2002
WO 0070047 A	23-11-2000	AU 5134600 A	05-12-2000
		EP 1179065 A	13-02-2002
		US 2002076762 A	20-06-2002